Moraes C, Witt G, Kuzikov M, Ellinger B, Calogeropoulou T, Prousis K, et al. Accelerating Drug Discovery Efforts for Trypanosomatidic Infections Using an Integrated Transnational Academic Drug Discovery Platform. SLAS Discov. 2019;24:346-361 pubmed publisher

Sonawane V, Siddique M, Gatchie L, Williams I, Bharate S, Jayaprakash V, et al. CYP enzymes, expressed within live human suspension cells, are superior to widely-used microsomal enzymes in identifying potent CYP1A1/CYP1B1 inhibitors: Identification of quinazolinones as CYP1A1/CYP1B1 inhibitors that efficiently reverse B[a]P toxi. Eur J Pharm Sci. 2019;131:177-194 pubmed publisher

Han L, Wang R, Wu B, Gu Y, Yuan Y. Effect of diammonium glycyrrhizinate on pharmacokinetics of omeprazole by regulating cytochrome P450 enzymes and plasma protein binding rate. Xenobiotica. 2019;49:975-980 pubmed publisher

Yi J, Kim Y, Lee Y, Bang O, Kim N. Effect of an ethanol extract of Descurainia sophia seeds on Phase I and II drug metabolizing enzymes and P-glycoprotein activity in vitro. BMC Complement Altern Med. 2015;15:441 pubmed publisher

Feng R, Shou J, Zhao Z, He C, Ma C, Huang M, et al. Transforming berberine into its intestine-absorbable form by the gut microbiota. Sci Rep. 2015;5:12155 pubmed publisher

Goldman J, Leeder J, van Haandel L, Pearce R. In Vitro Hepatic Oxidative Biotransformation of Trimethoprim. Drug Metab Dispos. 2015;43:1372-80 pubmed publisher

Tanino T, Funakami Y, Nagai N, Kato Y. Cyclosporin A-sensitive cytotoxicity of flurbiprofen non-stereoselectively mediated by cytochrome P450 metabolism in three-dimensional cultured rat hepatocytes. J Pharm Pharmacol. 2015;67:1406-15 pubmed publisher

Sasahara K, Shimokawa Y, Hirao Y, Koyama N, Kitano K, Shibata M, et al. Pharmacokinetics and Metabolism of Delamanid, a Novel Anti-Tuberculosis Drug, in Animals and Humans: Importance of Albumin Metabolism In Vivo. Drug Metab Dispos. 2015;43:1267-76 pubmed publisher

Sun Y, Jia P, Yuan L, Liu Y, Zhang Z, Du Y, et al. Investigating the in vitro stereoselective metabolism of m-nisoldipine enantiomers: characterization of metabolites and cytochrome P450 isoforms involved. Biomed Chromatogr. 2015;29:1893-900 pubmed publisher

Wang N, Gao C, Xue F, Han Y, Li T, Cao X, et al. Piezotronic-effect enhanced drug metabolism and sensing on a single ZnO nanowire surface with the presence of human cytochrome P450. ACS Nano. 2015;9:3159-68 pubmed publisher

Yamaori S, Takami K, Shiozawa A, Sakuyama K, Matsuzawa N, Ohmori S. In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction. Biol Pharm Bull. 2015;38:441-7 pubmed publisher

Uehara S, Uno Y, Inoue T, Murayama N, Shimizu M, Sasaki E, et al. Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus). Drug Metab Dispos. 2015;43:735-42 pubmed publisher

Gorissen B, Reyns T, Devreese M, De Backer P, Van Loco J, Croubels S. Determination of selected veterinary antimicrobials in poultry excreta by UHPLC-MS/MS, for application in Salmonella control programs. Anal Bioanal Chem. 2015;407:4447-57 pubmed publisher

Mosure K, Knipe J, Browning M, Arora V, Shu Y, Phillip T, et al. Preclinical Pharmacokinetics and In Vitro Metabolism of Asunaprevir (BMS-650032), a Potent Hepatitis C Virus NS3 Protease Inhibitor. J Pharm Sci. 2015;104:2813-23 pubmed publisher

Ning J, Yu Z, Hu L, Wang C, Huo X, Deng S, et al. Characterization of phase I metabolism of resibufogenin and evaluation of the metabolic effects on its antitumor activity and toxicity. Drug Metab Dispos. 2015;43:299-308 pubmed publisher

Guo W, Shi X, Wang W, Zhang W, Li J. Identification of the rat liver cytochrome P450 enzymes involved in the metabolism of the calcium channel blocker dipfluzine hydrochloride. Environ Toxicol Pharmacol. 2014;38:901-12 pubmed publisher

Wang W, Ni Y, Wang L, Che X, Liu W, Meng Q. Stereoselective oxidation metabolism of 20(S)-protopanaxatriol in human liver microsomes and in rats. Xenobiotica. 2015;45:385-95 pubmed publisher

Bi Y, Zhuang X, Zhu H, Song F, Liu Z, Liu S. Studies on metabolites and metabolic pathways of bulleyaconitine A in rat liver microsomes using LC-MS(n) combined with specific inhibitors. Biomed Chromatogr. 2015;29:1027-34 pubmed publisher

Shinde D, Kim M, Jeong E, Kim Y, Lee J, Shin J, et al. Enantioselective N-demethylation and hydroxylation of sibutramine in human liver microsomes and recombinant cytochrome p-450 isoforms. J Toxicol Environ Health A. 2014;77:1419-30 pubmed publisher

Wu J, Shaw J, Dubaisi S, Valeriote F, Li J. In vitro metabolism and drug-drug interaction potential of UTL-5g, a novel chemo- and radioprotective agent. Drug Metab Dispos. 2014;42:2058-67 pubmed publisher

Ogawa Y, Irikura M, Kobaru Y, Tomiyasu M, Kochiyama Y, Uriu M, et al. Population pharmacokinetics of doxapram in low-birth-weight Japanese infants with apnea. Eur J Pediatr. 2015;174:509-18 pubmed publisher

Thelingwani R, Bonn B, Chibale K, Masimirembwa C. Physicochemical and drug metabolism characterization of a series of 4-aminoquinoline-3-hydroxypyridin-4-one hybrid molecules with antimalarial activity. Expert Opin Drug Metab Toxicol. 2014;10:1313-24 pubmed publisher

Tse S, Leung L, Raje S, Seymour M, Shishikura Y, Obach R. Disposition and metabolic profiling of [(14)C]cerlapirdine using accelerator mass spectrometry. Drug Metab Dispos. 2014;42:2023-32 pubmed publisher

Yamamiya I, Yoshisue K, Ishii Y, Yamada H, Yoshida K. Species variation in the enantioselective metabolism of tegafur to 5-fluorouracil among rats, dogs and monkeys. J Pharm Pharmacol. 2014;66:1686-97 pubmed publisher

Dinger J, Meyer M, Maurer H. Development of an in vitro cytochrome P450 cocktail inhibition assay for assessing the inhibition risk of drugs of abuse. Toxicol Lett. 2014;230:28-35 pubmed publisher

Nirogi R, Palacharla R, Uthukam V, Manoharan A, Srikakolapu S, Kalaikadhiban I, et al. Chemical inhibitors of CYP450 enzymes in liver microsomes: combining selectivity and unbound fractions to guide selection of appropriate concentration in phenotyping assays. Xenobiotica. 2015;45:95-106 pubmed publisher

Yang B, Liu W, Chen K, Wang Z, Wang C. Metabolism of diosbulbin B in vitro and in vivo in rats: formation of reactive metabolites and human enzymes involved. Drug Metab Dispos. 2014;42:1737-50 pubmed publisher

Lin D, Li C, Peng Y, Gao H, Zheng J. Cytochrome p450-mediated metabolic activation of diosbulbin B. Drug Metab Dispos. 2014;42:1727-36 pubmed publisher

Barnes K, Rowland A, Polasek T, Miners J. Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. Eur J Clin Pharmacol. 2014;70:1097-106 pubmed publisher

Zhu L, Liu X, Zhu L, Zhang X, Fu X, Huang J, et al. Identification of human cytochrome P450 isozymes involved in the metabolism of naftopidil enantiomers in vitro. J Pharm Pharmacol. 2014;66:1534-51 pubmed publisher

Yuan L, Jia P, Sun Y, Zhao C, Zhi X, Sheng N, et al. Study of in vitro metabolism of m-nisoldipine in human liver microsomes and recombinant cytochrome P450 enzymes by liquid chromatography-mass spectrometry. J Pharm Biomed Anal. 2014;97:65-71 pubmed publisher

Zhao Y, Zhou L, Pan S, Zhan P, Chen X, Jin M. Fast determination of 22 sulfonamides from chicken breast muscle using core-shell nanoring amino-functionalized superparamagnetic molecularly imprinted polymer followed by liquid chromatography-tandem mass spectrometry. J Chromatogr A. 2014;1345:17-28 pubmed publisher

Li L, Tu M, Yang X, Sun S, Wu X, Zhou H, et al. The contribution of human OCT1, OCT3, and CYP3A4 to nitidine chloride-induced hepatocellular toxicity. Drug Metab Dispos. 2014;42:1227-34 pubmed publisher

Zhang X, Zhang J, Li W, Liu L, Sun B, Guo Z, et al. In vitro metabolism of 20(R)-25-methoxyl-dammarane-3, 12, 20-triol from Panax notoginseng in human, monkey, dog, rat, and mouse liver microsomes. PLoS ONE. 2014;9:e94962 pubmed publisher

Mooiman K, Goey A, Huijbregts T, Maas Bakker R, Beijnen J, Schellens J, et al. The in-vitro effect of complementary and alternative medicines on cytochrome P450 2C9 activity. J Pharm Pharmacol. 2014;66:1339-46 pubmed publisher

Ericsson T, Sundell J, Torkelsson A, Hoffmann K, Ashton M. Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies. Xenobiotica. 2014;44:615-26 pubmed publisher

Jin X, Pybus B, Marcsisin R, Logan T, Luong T, Sousa J, et al. An LC-MS based study of the metabolic profile of primaquine, an 8-aminoquinoline antiparasitic drug, with an in vitro primary human hepatocyte culture model. Eur J Drug Metab Pharmacokinet. 2014;39:139-46 pubmed

Martinkova M, Kubickova B, Stiborova M. Effects of cytochrome P450 inhibitors on peroxidase activity. Neuro Endocrinol Lett. 2012;33 Suppl 3:33-40 pubmed

Myung S, Yoon J, Yu S. STAT3 & Cytochrome P450 2C9: a novel signaling pathway in liver cancer stem cells. Biomed Pharmacother. 2012;66:612-6 pubmed publisher

Hama S, Ishihara Y, Watanabe M, Danjo S, Nakamura Y, Itoh K. Effects of sulfaphenazole after collagenase-induced experimental intracerebral hemorrhage in rats. Biol Pharm Bull. 2012;35:1849-53 pubmed

Ishihara Y, Shimamoto N. Sulfaphenazole attenuates myocardial cell apoptosis accompanied with cardiac ischemia-reperfusion by suppressing the expression of BimEL and Noxa. J Pharmacol Sci. 2012;119:251-9 pubmed

Brunt V, Minson C. KCa channels and epoxyeicosatrienoic acids: major contributors to thermal hyperaemia in human skin. J Physiol. 2012;590:3523-34 pubmed publisher

Locuson C, Alfaro J, Zaya M, Billen D, White J, Jones J. A non-acidic sulfaphenazole analog demonstrating high intrinsic clearance and selectivity by canine CYP2C21. Drug Metab Lett. 2011;5:253-8 pubmed

Choi Y, Lee M. Pharmacokinetic and pharmacodynamic interaction between nifedipine and metformin in rats: competitive inhibition for metabolism of nifedipine and metformin by each other via CYP isozymes. Xenobiotica. 2012;42:483-95 pubmed publisher

Vestergren A, Zlabek V, Pickova J, Zamaratskaia G. Tolbutamide hydroxylation by hepatic microsomes from Atlantic salmon (Salmo salar L.). Mol Biol Rep. 2012;39:6867-73 pubmed publisher

Liu Z, Shi Q, Ding D, Kelly R, Fang H, Tong W. Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS Comput Biol. 2011;7:e1002310 pubmed publisher

Wang F, Li J, Sinn A, Knabe W, Khanna M, Jo I, et al. Virtual screening targeting the urokinase receptor, biochemical and cell-based studies, synthesis, pharmacokinetic characterization, and effect on breast tumor metastasis. J Med Chem. 2011;54:7193-205 pubmed publisher

Ly V, Brock B. Effects of CYP inhibitors on precocene I metabolism and toxicity in rat liver slices. Chem Biol Interact. 2011;193:109-18 pubmed publisher

Lucas S, Negri M, Heim R, Zimmer C, Hartmann R. Fine-tuning the selectivity of aldosterone synthase inhibitors: structure-activity and structure-selectivity insights from studies of heteroaryl substituted 1,2,5,6-tetrahydropyrrolo[3,2,1-ij]quinolin-4-one derivatives. J Med Chem. 2011;54:2307-19 pubmed publisher

Marchais Oberwinkler S, Wetzel M, Ziegler E, Kruchten P, Werth R, Henn C, et al. New drug-like hydroxyphenylnaphthol steroidomimetics as potent and selective 17?-hydroxysteroid dehydrogenase type 1 inhibitors for the treatment of estrogen-dependent diseases. J Med Chem. 2011;54:534-47 pubmed publisher

Fraga A, da Silva L, Fraga C, Barreiro E. CYP1A2-mediated biotransformation of cardioactive 2-thienylidene-3,4-methylenedioxybenzoylhydrazine (LASSBio-294) by rat liver microsomes and human recombinant CYP enzymes. Eur J Med Chem. 2011;46:349-55 pubmed publisher

Kimura Y, Ito H, Hatano T. Effects of mace and nutmeg on human cytochrome P450 3A4 and 2C9 activity. Biol Pharm Bull. 2010;33:1977-82 pubmed

Rao K, Suman S, Kiran Y, Kuanr A, Gupta A, Bhalla K, et al. Co-expression of recombinant human CYP2C9 with human cytochrome P450 reductase in protease deficient S. cerevisiae strain at a higher scale yields an enzyme of higher specific activity. Drug Metab Lett. 2010;4:246-53 pubmed

Ishihara Y, Sekine M, Hamaguchi A, Kobayashi Y, Harayama T, Nakazawa M, et al. Effects of sulfaphenazole derivatives on cardiac ischemia-reperfusion injury: association of cytochrome P450 activity and infarct size. J Pharmacol Sci. 2010;113:335-42 pubmed

Zhang L, Hu X, Wang P, Zhang L. [Metabolism of osthol in isolated hepatocytes of rat]. Yao Xue Xue Bao. 2009;44:1131-5 pubmed

Virdis A, Cetani F, Giannarelli C, Banti C, Ghiadoni L, Ambrogini E, et al. The sulfaphenazole-sensitive pathway acts as a compensatory mechanism for impaired nitric oxide availability in patients with primary hyperparathyroidism. Effect of surgical treatment. J Clin Endocrinol Metab. 2010;95:920-7 pubmed publisher

Fourches D, Barnes J, Day N, Bradley P, Reed J, Tropsha A. Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chem Res Toxicol. 2010;23:171-83 pubmed publisher

Huang C, Liu W, Perry C, Yitzhaki S, Lee Y, Yuan H, et al. Autophagy and protein kinase C are required for cardioprotection by sulfaphenazole. Am J Physiol Heart Circ Physiol. 2010;298:H570-9 pubmed publisher

Brown N, Pretorius M. Letter by Brown and Pretorius regarding article, "effect of sulfaphenazole on tissue plasminogen activator release in normotensive subjects and hypertensive patients". Circulation. 2009;120:e159; author reply e160 pubmed publisher

Kazui M, Nishiya Y, Ishizuka T, Hagihara K, Farid N, Okazaki O, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos. 2010;38:92-9 pubmed publisher

Krotz F, Hellwig N, Bürkle M, Lehrer S, Riexinger T, Mannell H, et al. A sulfaphenazole-sensitive EDHF opposes platelet-endothelium interactions in vitro and in the hamster microcirculation in vivo. Cardiovasc Res. 2010;85:542-50 pubmed publisher

Toda T, Eliasson E, Ask B, Inotsume N, Rane A. Roles of different CYP enzymes in the formation of specific fluvastatin metabolites by human liver microsomes. Basic Clin Pharmacol Toxicol. 2009;105:327-32 pubmed publisher

Liu Z, Zeng S. Cytotoxicity of ginkgolic acid in HepG2 cells and primary rat hepatocytes. Toxicol Lett. 2009;187:131-6 pubmed publisher

Ishihara Y, Sekine M, Nakazawa M, Shimamoto N. Suppression of myocardial ischemia-reperfusion injury by inhibitors of cytochrome P450 in rats. Eur J Pharmacol. 2009;611:64-71 pubmed publisher

Lenasi H. The role of nitric oxide- and prostacyclin-independent vasodilatation in the human cutaneous microcirculation: effect of cytochrome P450 2C9 inhibition. Clin Physiol Funct Imaging. 2009;29:263-70 pubmed publisher

Pérez Garrido A, Morales Helguera A, Abellán Guillén A, Cordeiro M, Garrido Escudero A. Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins. Bioorg Med Chem. 2009;17:896-904 pubmed publisher

Lucas S, Heim R, Ries C, Schewe K, Birk B, Hartmann R. In vivo active aldosterone synthase inhibitors with improved selectivity: lead optimization providing a series of pyridine substituted 3,4-dihydro-1H-quinolin-2-one derivatives. J Med Chem. 2008;51:8077-87 pubmed publisher

Khan M, Mohan I, Kutala V, Kotha S, Parinandi N, Hamlin R, et al. Sulfaphenazole protects heart against ischemia-reperfusion injury and cardiac dysfunction by overexpression of iNOS, leading to enhancement of nitric oxide bioavailability and tissue oxygenation. Antioxid Redox Signal. 2009;11:725-38 pubmed publisher

Chang S, Li W, Traeger S, Wang B, Cui D, Zhang H, et al. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(-)-ibuprofen hydroxylation in vitro. Drug Metab Dispos. 2008;36:2513-22 pubmed publisher

Lucas S, Heim R, Negri M, Antes I, Ries C, Schewe K, et al. Novel aldosterone synthase inhibitors with extended carbocyclic skeleton by a combined ligand-based and structure-based drug design approach. J Med Chem. 2008;51:6138-49 pubmed publisher

Heim R, Lucas S, Grombein C, Ries C, Schewe K, Negri M, et al. Overcoming undesirable CYP1A2 inhibition of pyridylnaphthalene-type aldosterone synthase inhibitors: influence of heteroaryl derivatization on potency and selectivity. J Med Chem. 2008;51:5064-74 pubmed publisher

Frotscher M, Ziegler E, Marchais Oberwinkler S, Kruchten P, Neugebauer A, Fetzer L, et al. Design, synthesis, and biological evaluation of (hydroxyphenyl)naphthalene and -quinoline derivatives: potent and selective nonsteroidal inhibitors of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) for the treatment of estrogen-dependent di. J Med Chem. 2008;51:2158-69 pubmed publisher

Diamandis P, Wildenhain J, Clarke I, Sacher A, Graham J, Bellows D, et al. Chemical genetics reveals a complex functional ground state of neural stem cells. Nat Chem Biol. 2007;3:268-73 pubmed

Liverton N, Bednar R, Bednar B, Butcher J, Claiborne C, Claremon D, et al. Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist. J Med Chem. 2007;50:807-19 pubmed

Ekins S, Mankowski D, Hoover D, Lawton M, Treadway J, Harwood H. Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007;35:493-500 pubmed

Matsumoto M, Hashizume H, Tomishige T, Kawasaki M, Tsubouchi H, Sasaki H, et al. OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. PLoS Med. 2006;3:e466 pubmed